Page 26 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nicox Provides First Quarter 2021 Business Update and Financial Highlights NCX 470 Phase 3 trials in glaucoma on track for top-line results in top-line Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the "Nicox Group"), and updated key expected value-inflection milestones. Key Expected Milestones program in glaucoma : Nicox's lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog...

. The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity. The trial was laun...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... Erytech Pharma S.A.April 19, 2021 GMT ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients Trial will be escalated to the next dose Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 – ERYTECH Pharma (Nasd...

IS NOW APPROVED IN BRAZIL SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). VYZULTA is indicated for the reduction of intraocular pre...

Bausch Health Companies Inc. Bausch + Lomb, its leading global eye health business, and Nicox an international ophthalmology company, today announced that VYZULTA® 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency . VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other ...